I am not sure that I have added anything very dramatic in the last six months. But the slow accumulation of material makes it time for an update. And I want to assure you that I have not stopped work.
I have revised the thymoma and thymic carcinoma section. A thymoma panel is being set up in the United Kingdom and I hope I may be able to link images from the cases that we accumulate. I know that this will constitute a disproportionate emphasis, but I regard the vade mecum partially as a technology demonstration: I want to see how the inclusion of images within a limited domain works.
Osteopontin offers promise in the difficult differential between benign and malignant mesothelium. More studies are needed.
Two mitoses-specific antibodies, MPM-2 and Phospho-Histone H3, have been available for some time but have not been widely exploited to facilitated precise mitotic counts.
Happy New Year to you all.
Paul